[
  {
    "ts": "2025-01-07T12:00:00+00:00",
    "headline": "BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.",
    "url": "https://finance.yahoo.com/news/bio-techne-successful-second-claim-120000192.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d2b12539-287e-3c78-9d1d-526dfac92521",
      "content": {
        "id": "d2b12539-287e-3c78-9d1d-526dfac92521",
        "contentType": "STORY",
        "title": "BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC",
        "description": "",
        "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.",
        "pubDate": "2025-01-07T12:00:00Z",
        "displayTime": "2025-01-07T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c",
          "originalWidth": 400,
          "originalHeight": 146,
          "caption": "BT Logo (PRNewsfoto/Bio-Techne Corporation)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kJl8lfxgQq52fwY.Vvxfgw--~B/aD0xNDY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c.cf.webp",
              "width": 400,
              "height": 146,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tkFsOYbYoGS0nXbE3BaqwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-successful-second-claim-120000192.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-successful-second-claim-120000192.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]